Premium
Asymmetric Synthesis of Potential Precursors of the HIV Drug MC1220 and Its Analogues by Hydrogenation of (1‐Arylvinyl)pyrimidines
Author(s) -
Loksha Yasser M.,
Pedersen Erik B.
Publication year - 2018
Publication title -
journal of heterocyclic chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.321
H-Index - 59
eISSN - 1943-5193
pISSN - 0022-152X
DOI - 10.1002/jhet.3168
Subject(s) - chemistry , enantioselective synthesis , rhodium , asymmetric hydrogenation , catalysis , pyrimidine , steric effects , combinatorial chemistry , double bond , ruthenium , derivative (finance) , iridium , medicinal chemistry , stereochemistry , organic chemistry , financial economics , economics
Because MC1220 is a promising microbicide with anti‐HIV‐1 activity, the possibility for asymmetric synthesis of its potential precursors is explored. Here, we investigate asymmetric reduction of the vinyl double bond of 6‐(1‐arylvinyl)pyrimidine derivatives to their corresponding ethylidene analogues. Catalysts with ligands bearing trivalent phosphorus ligating the soft metals rhodium(I), ruthenium(II), or iridium(I) are used for asymmetric reduction of the vinyl derivatives 5a – e . The enantioselective reduction reaches 92% ee and about 71% conversion for reduction of the 6‐(1‐(3,5‐dimethylphenyl)vinyl)pyrimidine derivative 5b using the asymmetric catalyst catASium M(R)Rh ( 7m ). However, for the more sterically hindered double bond in the corresponding 2,6‐difluorophenyl derivative 5e , the enantioselective reduction dropped to 30% ee and 14% conversion.